Elevance Health Inc.
ELV
NYSE·Healthcare·Medical - Healthcare Plans·Mkt cap $88.4B
$407.50
▼ -1.76%
P/E
28.12
Mkt Cap
$88.4B
52-Wk Range
$274.84–$436.24
52-Week Range
$274.84 - $436.24
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 32.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive National Healthcare Network
- Advanced Digital Health Technology
- Comprehensive Care Ecosystem
- Strong Data Analytics Capabilities
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Telehealth Expansion
Value
Attractively priced below Managed Care & Health Insurance peer average
Momentum
Stable
-2.5% over 3m
Quality
Stable
Excellent business quality
Dividend
Modest
1.68% yield
Smart-money signal
Who's buying ELV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 20, 2026
JUL 15, 2026
Reported EPS of $7.45 vs $6.21 consensus (+20.0% surprise). Revenue of $49.8B vs $48.9B expected (+1.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+20.0%
Revenue trend · last 8Q
—
+7%
+15%
+14%
+12%
+9%
+3%
+1%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$45.1B
$45.4B
$48.9B
$49.8B
$50.7B
$49.7B
$50.2B
$50.5B
Margins · last 8Q
Gross
89.1%
Operating
78.1%
Profit
2.9%
Wall Street consensus
17 analysts · 76% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
76%
Hold
24%
Sell
0%
Median Price Target
—
Latest: Goldman Sachs · Jul 16, 2026
vs Industry
How ELV stacks vs Medical - Healthcare Plans
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related